Kisqali (600 MG Dose) and Polatuzumab Vedotin-piiq
Determining the interaction of Kisqali (600 MG Dose) and Polatuzumab Vedotin-piiq and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. No data are available for other, less potent CYP450 3A4 inhibitors. MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. No data are available for other, less potent CYP450 3A4 inhibitors.
MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (600 MG Dose)-Polio vaccine, inactivated
- Kisqali (600 MG Dose)-Poliovirus Vaccine (Inactivated)
- Kisqali (600 MG Dose)-Poliovirus vaccine, inactivated Injection
- Kisqali (600 MG Dose)-Polivy
- Kisqali (600 MG Dose)-Polmon
- Kisqali (600 MG Dose)-Polocaine
- Polatuzumab Vedotin-piiq-Kisqali Femara Co-Pack
- Polatuzumab Vedotin-piiq-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Polatuzumab Vedotin-piiq-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Polatuzumab Vedotin-piiq-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Polatuzumab Vedotin-piiq-Kitabis Pak
- Polatuzumab Vedotin-piiq-Kitabis Pak inhalation